The learning curve of single‐port extraperitoneal robotic radical prostatectomy: Initial experience and outcomes from a newly graduated fellowship‐trained robotic surgeon
BJUI Compass · 2026-03 · 7 (3)
DOI: 10.1002/bco2.70184 ↗At a glance
Journal article in BJUI Compass, published online on 2026-03-10. Written by Jacob S Hershenhouse and 11 co-authors. Institution: Catherine and Joseph Aresty Department of Urology USC Institute of Urology, Keck School of Medicine Los Angeles California USA. Cited 4 times so far (Crossref); 23 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Introduction and Objective This study aims to evaluate the learning curve and perioperative outcomes of single‐port extraperitoneal robotic radical prostatectomy (SP‐EP‐RARP) performed by a single surgeon at a high‐volume academic institution.
Methods
A retrospective review of a prospectively maintained database was conducted for patients who underwent SP‐EP‐RARP from September 2023 to August 2025. Key metrics included operative time, estimated blood loss, conversion rate, nerve‐sparing status, pathological margin status and continence (0–1 pad for safety), and 30‐day complication rate. Descriptive statistics were used, and outcomes were analysed chronologically to assess for trends suggesting a learning curve.
Results
The cohort included 53 patients who underwent extraperitoneal SP‐EP‐RARP. Median operative time was 213 min (IQR: 145–281). Median estimated blood loss was 100 mL (IQR: 75–125). Nerve‐sparing was attempted in 75.5% of cases. No assist or plus one ports were utilized. Final pathology revealed pT2 disease in 64.1% (34 cases), pT3a in 32.1% (17 cases) and pT3b in 3.7% (2 cases). Overall positive margin rate was 26.4%. Thirty‐day Clavien–Dindo Grades I–II complication rates were 11.3%, and no major complications or 90‐day complications were reported. Continence rates at 6 weeks, 3 months and 6 months were 72%, 72% and 75%, respectively. Stabilization of operative times and intraoperative outcomes occurred after approximately 25–30 cases.
Conclusion
SP‐EP‐RARP can be safely implemented by a newly graduated fellowship‐trained robotic surgeon with acceptable oncologic and functional outcomes. Initial learning can be estimated at approximately 25–30 cases.
Subjects
Author keywords
Authors and institutions
- Catherine and Joseph Aresty Department of Urology USC Institute of Urology, Keck School of Medicine Los Angeles California USA.
- Department of Urology Mayo Clinic Jacksonville Florida USA.
- Glickman Urological Institute Cleveland Clinic Cleveland Ohio USA.
- Department of Urology Icahn School of Medicine at Mount Sinai New York New York USA.
- Department of Urology University of Illinois at Chicago Chicago Illinois USA.
ORCID profiles: Jacob S Hershenhouse, Riccardo Autorino, Ketan K Badani
Cite
APA
Hershenhouse, J. S., Kim, S., Gevorkyan, R., Hom, B., Eppler, M., Ford, P., Pathak, R., Autorino, R., Abreu, A., Badani, K. K., Crivellaro, S., & Hemal, S. (2026). The learning curve of single‐port extraperitoneal robotic radical prostatectomy: Initial experience and outcomes from a newly graduated fellowship‐trained robotic surgeon. BJUI Compass, 7(3). https://doi.org/10.1002/bco2.70184
Vancouver
Hershenhouse JS, Kim S, Gevorkyan R, Hom B, Eppler M, Ford P, et al. The learning curve of single‐port extraperitoneal robotic radical prostatectomy: Initial experience and outcomes from a newly graduated fellowship‐trained robotic surgeon. BJUI Compass. 2026;7(3). doi:10.1002/bco2.70184
BibTeX
@article{Hershenhouse2026,
author = {Hershenhouse, Jacob S and Kim, Simon and Gevorkyan, Rafael and Hom, Brian and Eppler, Michael and Ford, Patrick and Pathak, Ram and Autorino, Riccardo and Abreu, Andre and Badani, Ketan K and Crivellaro, Simone and Hemal, Sij},
title = {The learning curve of single‐port extraperitoneal robotic radical prostatectomy: Initial experience and outcomes from a newly graduated fellowship‐trained robotic surgeon},
journal = {BJUI Compass},
year = {2026},
volume = {7},
number = {3},
doi = {10.1002/bco2.70184}
}
EUVIMED